UCB SA (OTCMKTS:UCBJY) Sees Significant Growth in Short Interest

UCB SA (OTCMKTS:UCBJYGet Rating) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 33,300 shares, a growth of 35.9% from the June 30th total of 24,500 shares. Based on an average trading volume of 70,100 shares, the short-interest ratio is currently 0.5 days.

UCB Stock Down 1.8 %

Shares of UCBJY stock opened at $39.00 on Monday. UCB has a one year low of $38.55 and a one year high of $63.94. The company’s 50-day simple moving average is $42.68 and its 200-day simple moving average is $50.12.

Wall Street Analyst Weigh In

Several brokerages have weighed in on UCBJY. Societe Generale cut their price target on UCB from €111.00 ($113.27) to €106.00 ($108.16) and set a “buy” rating for the company in a report on Monday, June 27th. Deutsche Bank Aktiengesellschaft dropped their price objective on UCB from €95.00 ($96.94) to €90.00 ($91.84) in a report on Tuesday, June 7th. UBS Group dropped their price objective on UCB from €95.00 ($96.94) to €87.00 ($88.78) and set a “neutral” rating for the company in a report on Monday, June 27th. Morgan Stanley downgraded UCB from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 19th. Finally, Berenberg Bank dropped their price objective on UCB from €122.00 ($124.49) to €120.00 ($122.45) and set a “buy” rating for the company in a report on Friday, May 20th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $100.75.

About UCB

(Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.